[Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].

Abstract

Small cell lung cancer (SCLC) is a poorly differentiated high-grade neuroendocrine tumor, accounts for approximately 14% of all lung cancers. SCLC is characterized by rapid growth, early metastasis without effective treatments after recurrence. It is urgently need to improve the therapy of patients with SCLC. In recent years Tumor immunotherapy has shown… (More)
DOI: 10.3779/j.issn.1009-3419.2017.09.06

Topics

  • Presentations referencing similar topics